Basis: Four-quarter operating cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The operating cash flow yield is N/A as of 2026-10-06T21:57:14.285Z.
Calculation as of: 2026-10-06T21:57:14.285Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 610e9c20fcdf10729c15ba1bd616707a7081826ce2aba31979c935d5001cdfd8
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
OPERATING CASH FLOW YIELD
N/A
Kailera Therapeutics, Inc.
Market Cap
$1.40B
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.40B
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.40B
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.39B
Operating Cash Flow Yield
3.84%
TTM Avg
4.59%
3Y Avg
4.10%
5Y Avg
4.07%
Market Cap
$1.42B
Operating Cash Flow Yield
1.28%
TTM Avg
0.67%
3Y Avg
0.67%
5Y Avg
1.44%
Market Cap
$1.42B
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.37B
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.44B
Operating Cash Flow Yield
5.75%
TTM Avg
8.38%
3Y Avg
5.38%
5Y Avg
4.20%
Market Cap
$1.45B
Operating Cash Flow Yield
10.84%
TTM Avg
10.55%
3Y Avg
6.87%
5Y Avg
5.24%
| NAME | MARKET CAP | OPERATING CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Kailera Therapeutics, Inc. (KLRA) | $1.40B | N/A | N/A | N/A | N/A |
| Taysha Gene Therapies, Inc. (TSHA)vs › | $1.40B | N/A | N/A | N/A | N/A |
| Braveheart Bio, Inc. (BRVE)vs › | $1.40B | N/A | N/A | N/A | N/A |
| The Pennant Group, Inc. (PNTG)vs › | $1.39B | 3.84% | 4.59% | 4.10% | 4.07% |
| AnaptysBio, Inc. (ANAB)vs › | $1.42B | 1.28% | 0.67% | 0.67% | 1.44% |
| Ultragenyx Pharmaceutical Inc. (RARE)vs › | $1.42B | N/A | N/A | N/A | N/A |
| Inhibrx Biosciences Inc. (INBX)vs › | $1.37B | N/A | N/A | N/A | N/A |
| Certara, Inc. (CERT)vs › | $1.44B | 5.75% | 8.38% | 5.38% | 4.20% |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.45B | 10.84% | 10.55% | 6.87% | 5.24% |
| Maze Therapeutics, Inc. (MAZE)vs › | $1.46B | N/A | 14.73% | 14.73% | 14.73% |
OCF Yield = TTM Operating Cash Flow / Market Cap
Operating cash flow yield is the inverse of P/OCF, expressing trailing operating cash flow as a percentage of price. It sits between earnings yield (before non-cash accrual effects) and FCF yield (before capital expenditure).
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
